Buscador de ensayos clínicos de Fight CRC
NCT ID | Title | Fase | Date Added | Ubicación | Prior IO Allowed | CRC-directed | Status | Drogas | Etiquetas |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT04111172 |
TitleUna vacuna (Ad5.F35-hGCC-PADRE) para el tratamiento del adenocarcinoma gastrointestinal | Fase
Fase 2
|
Date Added 2019-10-01 |
Ubicación
Pennsylvania, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03566355 |
TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer | Fase
No aplicable
|
Date Added 2018-06-25 |
Ubicación
Corea, República de
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Fase
Fase 1
|
Date Added 2019-12-04 |
Ubicación
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Bélgica Canadá Alemania Italia Japón Corea, República de Países Bajos España Taiwán Reino Unido |
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03740256 |
TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Fase
Fase 1
|
Date Added 2018-11-14 |
Ubicación
Texas, United States
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
CAdVEC |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02453620 |
TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | Fase
Fase 1
|
Date Added 2015-05-25 |
Ubicación
California, United States
Connecticut, United States Maryland, United States Pennsylvania, United States |
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03170960 |
TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Fase
Fase 1
|
Date Added 2017-05-31 |
Ubicación
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Bélgica Francia Alemania Italia Países Bajos España Reino Unido |
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Atezolizumab, Cabozantinib |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03600883 |
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | Fase
Phase 1, Phase 2
|
Date Added 2018-07-26 |
Ubicación
California, United States
Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Bélgica Brasil Canadá Francia Alemania Greece Hungary Japón Corea, República de Portugal Romania España Suiza |
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Anti PD-1/L1, Midazolam, Sotorasib |
Etiquetas
MSS/ MMRp
|
NCT ID PG545 (pixatimod) in combination with nivolumab |
TitlePG545 (pixatimod) in combination with nivolumab | Fase
Fase 1
|
Date Added 2019-04-26 |
Ubicación |
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02668770 |
TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | Fase
Fase 1
|
Date Added 2016-01-29 |
Ubicación
Texas, United States
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Ipilimumab, MGN1703 |
Etiquetas
MSS/ MMRp
|
NCT ID NCT02285816 |
TitleMG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours | Fase
Phase 1, Phase 2
|
Date Added 2014-11-07 |
Ubicación
Canadá
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
AdMA3, MG1MA3 |
Etiquetas
MSS/ MMRp
|